Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$1.15 - $2.19 $5 - $10
5 Added 1.66%
307 $0
Q4 2023

Feb 09, 2024

BUY
$0.93 - $2.35 $17 - $44
19 Added 6.71%
302 $0
Q3 2023

Nov 13, 2023

BUY
$1.19 - $2.36 $8 - $16
7 Added 2.54%
283 $0
Q2 2023

Aug 15, 2023

BUY
$1.8 - $3.19 $27 - $47
15 Added 5.75%
276 $0
Q1 2023

May 12, 2023

BUY
$2.01 - $4.17 $8 - $16
4 Added 1.56%
261 $0
Q4 2022

Feb 13, 2023

SELL
$1.78 - $3.64 $8,791 - $17,977
-4,939 Reduced 95.05%
257 $0
Q3 2022

Nov 14, 2022

BUY
$2.89 - $5.32 $12,531 - $23,067
4,336 Added 504.19%
5,196 $15,000
Q2 2022

Aug 12, 2022

SELL
$3.27 - $8.76 $33,494 - $89,728
-10,243 Reduced 92.25%
860 $3,000
Q1 2022

May 16, 2022

SELL
$7.56 - $14.3 $92,972 - $175,861
-12,298 Reduced 52.55%
11,103 $91,000
Q4 2021

Feb 14, 2022

SELL
$12.24 - $21.25 $249,891 - $433,840
-20,416 Reduced 46.59%
23,401 $333,000
Q3 2021

Nov 15, 2021

SELL
$16.69 - $26.05 $27,955 - $43,633
-1,675 Reduced 3.68%
43,817 $843,000
Q2 2021

Aug 16, 2021

BUY
$18.15 - $27.75 $407,394 - $622,876
22,446 Added 97.4%
45,492 $1.15 Million
Q1 2021

May 13, 2021

SELL
$20.71 - $51.02 $520,028 - $1.28 Million
-25,110 Reduced 52.14%
23,046 $568,000
Q4 2020

Feb 09, 2021

BUY
$21.84 - $44.0 $166,180 - $334,796
7,609 Added 18.77%
48,156 $1.76 Million
Q3 2020

Nov 05, 2020

SELL
$13.63 - $24.12 $80,117 - $141,777
-5,878 Reduced 12.66%
40,547 $879,000
Q2 2020

Aug 13, 2020

BUY
$7.65 - $14.11 $119,171 - $219,805
15,578 Added 50.5%
46,425 $603,000
Q1 2020

May 14, 2020

BUY
$4.75 - $12.41 $146,523 - $382,811
30,847 New
30,847 $249,000

Others Institutions Holding PSNL

About Personalis, Inc.


  • Ticker PSNL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 45,918,400
  • Market Cap $256M
  • Description
  • Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or pla...
More about PSNL
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.